STOCK TITAN

Neogenomics Inc. - NEO STOCK NEWS

Welcome to our dedicated news page for Neogenomics (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neogenomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neogenomics's position in the market.

Rhea-AI Summary
NeoGenomics, Inc. (NASDAQ:NEO) will present new data on its RaDaR assay for minimal residual disease (MRD) at the 46th annual San Antonio Breast Cancer Symposium (SABCS). The data will feature an updated analysis of the TRACER study, showcasing the potential utility of RaDaR in early-stage breast cancer, including baseline detection, therapy response monitoring, and post-operative recurrence monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
conferences
-
Rhea-AI Summary
NeoGenomics, Inc. (NASDAQ:NEO) will participate in the Piper Sandler 35th Annual Global Healthcare Conference in New York City. Members of NeoGenomics' management team will engage in a fireside chat on November 29th at 9:00 a.m. Eastern Time. A live and archived audio webcast of the presentation will be accessible on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.71%
Tags
conferences
-
Rhea-AI Summary
NeoGenomics, Inc. reported an 18% increase in revenue for the third quarter of 2023, reaching $152 million. Clinical Services revenue increased by 20% to $128 million, while Advanced Diagnostics revenue increased by 8% to $24 million. The company also announced a decrease in net loss by 50% to $19 million and a significant increase in adjusted EBITDA by 129% to positive $3 million. NeoGenomics raised its full-year 2023 revenue guidance to a range of $585 million - $592 million and adjusted EBITDA guidance to a range of $4 million loss - $1 million loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.2%
Tags
Rhea-AI Summary
NeoGenomics announces the commercial availability of two new tests: Neo Comprehensive™ - Heme Cancers and Early-stage Non-Small Cell Lung Cancer (NSCLC) Panel. These tests provide comprehensive genomic profiles for hematologic malignancies and early-stage lung cancer, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.59%
Tags
none
-
Rhea-AI Summary
NeoGenomics to report Q3 2023 financial results on November 6th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.85%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
Neogenomics Inc.

Nasdaq:NEO

NEO Rankings

NEO Stock Data

1.80B
125.95M
1.18%
101.05%
5.67%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
US
Fort Myers

About NEO

neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig